Post by rockstarrick on Jan 4, 2019 20:20:19 GMT -5
I have been hanging around MNKD for awhile, probably longer than many on this board.
At this point not much surprises me but today's call did. I fully expected Mike to announce a special vote to approve another 150+k authorized shares. Instead he doubled down on the plan from last spring plus the addition of the migraine development and the announcement that MNKD is now funded through mid-2020.
This would seem not good news to those holding short and I would expect an orderly exit by most. What happens in 12 months is any ones guess. If Mike continues to delivery on the plan, afrezza sales continue to increase, Dr. Kendall makes inroads on changes to the SOC, maybe an international partner, may RLS comes out of the closet, etc. Sabby may not even consider shorting at what may be a bargain basement price less than $2.
With that said MNKD is clearly a take-over target for any company who wants to potentially get into the diabetes space in a big way if what VDex is saying in their white paper is correct. One of my take-aways from their paper is they verified what Al Mann was seeing in his studies years ago. I think if Dr. Kendall has had the chance to read it, it will be his impression too. Without the shares on the shelf I sure hope Mike has a plan, just in case.
Then the day that MNKD announced they were basically firing Sanofi, (1/6/2016), and the stock dropped to .64 cents, I bought 12k more shares, and sold those for around $3 to recouped a few bucks. Made some more cash back in October 2017, and just purchased a few more shares at a buck last week.
If Mike C does pull the rabbit out of the hat, I’m going to look like a genius. If not, I’ll just look like the Rock Star.
Wow, what a trip down memory lane.
✌🏻😎